Lipella Pharmaceuticals Inc. SEC filings LIPO
Lipella Pharmaceuticals Inc. has 225 filings in SEC EDGAR's recent list, going back to Dec 9, 2005. Its latest annual report, Form 10-K, was filed on Mar 28, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Nov 14, 2025, covering the quarter ended Sep 30, 2025. The most recent current report (Form 8-K) was filed on Jul 15, 2026 (bankruptcy). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy
|
Jul 15, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Bankruptcy
|
Mar 31, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 4, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 21, 2025 | Oct 20, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 9, 2025 | Oct 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 18, 2025 | Sep 18, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 25, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Jun 20, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Other events
|
Jun 16, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 16, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 15, 2025 | May 15, 2025 |
| 8-K |
Current report
Other events
|
Apr 14, 2025 | Apr 14, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 9, 2025 | Apr 9, 2025 |
| 8-K |
Current report
Material agreement
|
Apr 7, 2025 | Apr 7, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 11, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 3, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Material agreement
|
Feb 24, 2025 | Feb 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 11, 2025 | Feb 11, 2025 |
| 8-K |
Current report
Listing notice
|
Jan 13, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 6, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Dec 30, 2024 | Dec 30, 2024 |
| 8-K |
Current report
Other events
|
Dec 27, 2024 | Dec 27, 2024 |
| 8-K |
Current report
Other events
|
Dec 20, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 10, 2024 | Dec 5, 2024 |
| 8-K |
Current report
Other events
|
Dec 6, 2024 | Dec 6, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Other events
|
Nov 1, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Listing notice
|
Oct 18, 2024 | Oct 18, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Sep 11, 2024 | Sep 11, 2024 |
| 8-K |
Current report
Listing notice
|
Aug 23, 2024 | Aug 23, 2024 |
| 8-K |
Current report
Other events
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 1, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Listing notice
|
Apr 19, 2024 | Apr 19, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 12, 2024 | Apr 12, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 15, 2024 | Mar 15, 2024 |
| 8-K |
Current report
Other events
|
Dec 1, 2023 | Dec 1, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 28, 2023 | Nov 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Nov 22, 2023 | Nov 22, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 26, 2023 | Oct 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Material agreement
|
Aug 2, 2023 | Aug 2, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 1, 2023 | Jun 1, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2023 | May 15, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Apr 3, 2023 | Apr 3, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K/A | Amended current report | Feb 2, 2023 | Jan 11, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 12, 2023 | Jan 11, 2023 |
Showing 50 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LIPO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pittsburgh, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1347242
- Former names
- LIPELLA PHARMACEUTICALS INC (until Sep 11, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.